| Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.Orphanet J Rare Dis | PMID 39574155PMC11583740 | 2024-Nov-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018).J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39186709无 PMCID | 2024-Nov-20 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 无 KM 图 |
| Extent of Lymphadenectomy for Surgical Management of Right-Sided Colon Cancer: The Randomized Phase III RELARC Trial.J Clin Oncol | PMID 39190853无 PMCID | 2024-Nov-20 | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study.Acta Derm Venereol | PMID 39565228PMC11600607 | 2024-Nov-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury: The TRAIN Randomized Clinical Trial.JAMA | PMID 39382241PMC11581574 | 2024-Nov-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine.J Clin Endocrinol Metab | PMID 38412282无 PMCID | 2024-Nov-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial.BMJ | PMID 39557487PMC11571049 | 2024-Nov-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39550172无 PMCID | 2024-Nov-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-Like Reactions During Treatment of Latent Tuberculosis Infection.J Infect Dis | PMID 38640958PMC11489317 | 2024-Nov-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults.J Infect Dis | PMID 38889247PMC11566230 | 2024-Nov-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines.Aesthet Surg J | PMID 38913088PMC11566037 | 2024-Nov-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial.J Infect Dis | PMID 39028902PMC11566225 | 2024-Nov-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback.J Infect Dis | PMID 39036987PMC11566236 | 2024-Nov-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of attractive targeted sugar bait stations against malaria in Western Province Zambia: epidemiological findings from a two-arm cluster randomized phase III trial.Malar J | PMID 39548456PMC11566550 | 2024-Nov-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Preoperative Chemoradiotherapy for Resectable Gastric Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39282905无 PMCID | 2024-Nov-14 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 无 KM 图 |
| Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39282910无 PMCID | 2024-Nov-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective, multicenter phase III trial.Signal Transduct Target Ther | PMID 39532849PMC11557926 | 2024-Nov-13 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.J Patient Rep Outcomes | PMID 39535661PMC11561219 | 2024-Nov-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial.RMD Open | PMID 39537558PMC11575345 | 2024-Nov-13 | 0.90 | The study is a randomized phase III trial with a drug intervention (adalimumab) and reports original results, but it is not an oncology study (rheumatoid arthritis) and does not have a time-to-event efficacy endpoint. The primary outcomes are categorical (remission/low disease activity) and continuous (CRP levels), not survival or progression metrics. | 待处理 |
| Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial.J Am Coll Cardiol | PMID 39387764无 PMCID | 2024-Nov-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia: The Randomized, Phase 3 REMAIN-2 Trial.J Am Coll Cardiol | PMID 39505412无 PMCID | 2024-Nov-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial.Nat Commun | PMID 39532861PMC11557889 | 2024-Nov-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study.Arthritis Res Ther | PMID 39533349PMC11556075 | 2024-Nov-12 | 0.90 | The study is a randomized, Phase III clinical trial of a drug (upadacitinib) with original results, but it is not an oncology study (it investigates ankylosing spondylitis, a rheumatologic condition). Therefore, it fails the fundamental oncology criterion required for this cohort. | 待处理 |
| Effect of Esophageal Dilation History on Efficacy Outcomes in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension.Am J Gastroenterol | PMID 39631042PMC12208388 | 2024-Nov-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma).J Clin Oncol | PMID 39270145无 PMCID | 2024-Nov-10 | 0.90 | The study is an eligible Phase III randomized human oncology trial with primary time-to-event efficacy endpoints (EFS, OS). However, the intervention compares two types of transplantation (autologous vs. allogeneic hematopoietic stem cell transplantation), not a drug-containing intervention. Therefore, it does not meet the inclusion criteria for a drug intervention. | 待处理 |
| Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS.Lupus Sci Med | PMID 39521453PMC11552023 | 2024-Nov-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder: a pooled post hoc analysis of two randomized phase 3 clinical studies.Sleep | PMID 38644625PMC11543623 | 2024-Nov-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 38828984无 PMCID | 2024-Nov-07 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 38899716无 PMCID | 2024-Nov-07 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy.J Am Coll Cardiol | PMID 39217556无 PMCID | 2024-Nov-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy.J Am Coll Cardiol | PMID 39217563无 PMCID | 2024-Nov-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.J Am Coll Cardiol | PMID 39217569PMC11975529 | 2024-Nov-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial.JAMA | PMID 39264623PMC11393753 | 2024-Nov-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.J Am Coll Cardiol | PMID 39352339无 PMCID | 2024-Nov-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Weekly Calcifediol Formulations (75 and 100 µg) in Subjects with Vitamin D Deficiency: A Phase II/III Randomised Trial.Nutrients | PMID 39599585PMC11597509 | 2024-Nov-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Upadacitinib Induction and Maintenance Therapy on Health-related Quality of Life, Fatigue, and Work Productivity in Patients with Moderately-to-severely Active Crohn's Disease.J Crohns Colitis | PMID 38835235PMC11532615 | 2024-Nov-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin Therapy.J Crohns Colitis | PMID 38836628PMC11532613 | 2024-Nov-04 | 0.90 | The record describes a Phase 3, randomized trial in ulcerative colitis (not oncology) with drug interventions (infliximab, etrolizumab) and original results on clinical remission. However, it does not include a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier analysis, or HR) as required for inclusion in the cohort. | 待处理 |
| Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme.J Crohns Colitis | PMID 38869019PMC11532612 | 2024-Nov-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.J Crohns Colitis | PMID 38877972PMC11532610 | 2024-Nov-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Concordance of patient- and clinician-reported outcomes of acute radiation dermatitis in breast cancer.Support Care Cancer | PMID 39495339无 PMCID | 2024-Nov-04 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Recombinant Human Thyrotropin Plus Radioactive Iodine Among Patients With Thyroid Cancer: A Noninferiority Randomized Clinical Trial.JAMA Netw Open | PMID 39509132PMC11544486 | 2024-Nov-04 | 0.95 | The study meets most criteria (oncology, human, randomized, Phase III, original report, drug intervention) but fails the critical requirement of having a primary or key secondary time-to-event efficacy endpoint. The primary endpoint is a noninferiority comparison of success rates (binary outcome) at 6-8 months, not a survival or progression-free survival analysis with time-to-event methodology. | 待处理 |
| Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema.Transl Vis Sci Technol | PMID 39535745PMC11562974 | 2024-Nov-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials.Rheumatology (Oxford) | PMID 38331400PMC11534117 | 2024-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prehospital tranexamic acid is associated with a survival benefit without an increase in complications: Results of two harmonized randomized clinical trials.J Trauma Acute Care Surg | PMID 38523128PMC11422517 | 2024-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial.J Atheroscler Thromb | PMID 38616112PMC11537784 | 2024-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Application of Recombinant Human Superoxide Dismutase in Radical Concurrent Chemoradiotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Acute Rectal Injury: A Multicenter, Randomized, Open-label, Prospective Trial.Int J Radiat Oncol Biol Phys | PMID 38705489无 PMCID | 2024-Nov-01 | 0.45 | Trial meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, it is excluded because the primary and secondary endpoints are focused on the incidence and duration of radiation-induced acute rectal injury (diarrhea) and mucosal damage, which are safety/toxicity endpoints, not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR reporting. | 待处理 |
| Laparoscopic versus open pancreatoduodenectomy for periampullary tumors: a randomized clinical trial.Int J Surg | PMID 39172725PMC11573048 | 2024-Nov-01 | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials.JAMA Intern Med | PMID 39226070PMC11372653 | 2024-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial.JAMA Cardiol | PMID 39230885PMC11375526 | 2024-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Semen analysis and reproductive hormones in boys with classical Hodgkin lymphoma treated according to the EuroNet-PHL-C2 protocol.Hum Reprod | PMID 39256932PMC11532607 | 2024-Nov-01 | 0.45 | The record is an add-on study to a randomized phase-3 trial evaluating a drug-containing chemotherapy regimen for Hodgkin lymphoma in boys. However, it is not an original result report of the trial's primary efficacy endpoint (e.g., OS, PFS). Instead, it is a secondary analysis focusing on reproductive toxicity (semen parameters, hormones), which is a safety/quality-of-life-related outcome, not a primary time-to-event efficacy endpoint required for inclusion. | 待处理 |